BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody.
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody
Sanlorenzo, Martina;Novelli, Mauro;Macagno, Marco;Leuci, Valeria;Rotolo, Ramona;Donini, Chiara;Quaglino, Pietro;Fierro, Maria Teresa;Giordano, Silvia;Aglietta, Massimo;Sangiolo, Dario
Last
2018-01-01
Abstract
BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1078-0432.CCR-17-1914.full.pdf
Open Access dal 13/04/2019
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
1.89 MB
Formato
Adobe PDF
|
1.89 MB | Adobe PDF | Visualizza/Apri |
|
3377.full.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.17 MB
Formato
Adobe PDF
|
1.17 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
